Clinical trials: Elevated Prostate Specific Antigen
Neoplasms, Prostate
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth.
- Trial name
- NCT00470834
- Testing
- dutasteride, bicalutamide
- Where
- 62 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.
Prostate Cancer
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones.
- Trial name
- NCT00005073
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer
This study is an open-label extension to the double-blind GUP-0205-1 and double-blind extension GUP-0205-1XX studies. High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical…
- Trial name
- NCT00731848
- Testing
- pomegranate liquid extract
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roll International Corporation
Prostate Cancer
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
- Trial name
- NCT00061126
- Testing
- ABX-EGF
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abgenix
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostate Cancer
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
- Trial name
- NCT00050297
- Testing
- YM598
- Where
- 23 sites in Belgium, Czechia and 5 more
- Sponsor
- Astellas Pharma Inc
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasms
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy.
- Trial name
- NCT02771769
- Testing
- blood draw
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chronix Biomedical Corporation